Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/243555
Type: Artigo de periódico
Title: Low Educational Level But Not Low Income Impairs The Achievement Of Cytogenetic Remission In Chronic Myeloid Leukemia Patients Treated With Imatinib In Brazil
Author: Fortes Rego
Monica Napoleao; Metze
Konradin; Lorand-Metze
Irene
Abstract: OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Unico de Saude (SUS). We studied the socio-demographic factors that influenced therapy success in a population in the northeast region of Brazil. METHODS: Patients with chronic myeloid leukemia from the state of Piaui were treated in only one reference center. Diagnosis was based on WHO 2008 criteria. Risk was assessed by Sokal, Hasford and EUTOS scores. Patients received 400 mg imatinib daily. We studied the influence of the following factors on the achievement of complete cytogenetic response within one year of treatment: age, clinical risk category, time interval between diagnosis and the start of imatinib treatment, geographic distance from the patient's home to the hospital, years of formal education and monthly income. RESULTS: Among 103 patients studied, the median age was 42 years; 65% of the patients had 2-9 years of formal education, and the median monthly income was approximately 100 US$. Imatinib was started in the first year after diagnosis (early chronic phase) in 69 patients. After 12 months of treatment, 68 patients had a complete cytogenetic response. The Hasford score, delay to start imatinib and years of formal education influenced the attainment of a complete cytogenetic response, whereas income and the distance from the home to the healthcare facility did not. CONCLUSION: Patients require additional healthcare information to better understand the importance of long-term oral anticancer treatment and to improve their compliance with the treatment.
Subject: Survival
Interferon
Adherence
Mortality
Score
Country: SAO PAULO
Editor: HOSPITAL CLINICAS, UNIV SAO PAULO
Rights: fechado
Identifier DOI: 10.6061/clinics/2015(05)03
Address: http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1807-59322015000500322&lng=en&nrm=iso
Date Issue: 2015
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
wos_000355800500003.pdf350.09 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.